Format

Send to

Choose Destination
Clin Microbiol Infect. 2012 Jul;18(7):E248-50. doi: 10.1111/j.1469-0691.2012.03890.x. Epub 2012 Apr 30.

EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole.

Author information

1
Unit of Mycology and Parasitology, Department of Microbiological Surveillance and Research, Statens Serum Institute, Copenhagen, Denmark. maca@ssi.dk

Abstract

The European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has determined breakpoints for amphotericin B, itraconazole and posaconazole for Aspergillus species. This Technical Note is based on the EUCAST amphotericin B, itraconazole and posaconazole rationale documents (available on the EUCAST website: http://www.eucast.org/antifungal_susceptibility_testing_afst/rationale_documents_for_antifungals/). The amphotericin B and itraconazole breakpoints are based on epidemiological cut-off values and clinical experience. The posaconazole breakpoints are also based on pharmacokinetic and pharmacodynamic data. Breakpoints will be reviewed regularly or when new data emerge.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center